British scientists found that three monoclonal antibodies, anti-41BB, anti-CD40 and anti-CTLA4, proved effective in killing 40% to 60% of neuroblastoma in laboratory tests. The antibodies attack cancer cells by recognizing and activating the immune system's response. "It is hoped that these antibodies can be used to boost or 'super charge' the body's immune system to help it fight cancer," the researchers said.

Full Story:

Related Summaries